Skip to content


Brilinta, Brilique (ticagrelor) is a small molecule pharmaceutical. Ticagrelor was first approved as Brilinta on 2010-12-03. It has been approved in Europe to treat acute coronary syndrome and peripheral vascular diseases. The pharmaceutical is active against P2Y purinoceptor 12. In addition, it is known to target equilibrative nucleoside transporter 1. Brilinta's patents are valid until 2036-01-27 (FDA).
Trade Name Brilique
Common Name Ticagrelor
Indication acute coronary syndrome, peripheral vascular diseases
Drug Class Platelet aggregation inhibitors
Get full access now